Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink
Portfolio Pulse from Vandana Singh
Bausch + Lomb Corporation (NYSE:BLCO) has acquired Johnson & Johnson's (NYSE:JNJ) eye and contact lens drops brand Blink for $106.5 million. This is the second acquisition in two weeks aimed at bolstering Bausch + Lomb's portfolio of eye care products. Last week, the company struck a $1.75 billion deal with Novartis AG (NYSE:NVS) to buy several eye-care products.
July 06, 2023 | 4:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bausch + Lomb's acquisition of Blink from JNJ and other eye-care products from NVS could strengthen its position in the eye care market.
The acquisition of Blink and other eye-care products could potentially increase Bausch + Lomb's market share and revenues in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Johnson & Johnson has sold its eye and contact lens drops brand Blink to Bausch + Lomb for $106.5 million.
The sale of Blink could result in a short-term cash influx for JNJ, but it's unclear how it will impact the company's long-term strategy.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Novartis AG sold several eye-care products to Bausch + Lomb in a $1.75 billion deal.
The sale of these products could result in a short-term cash influx for NVS, but it's unclear how it will impact the company's long-term strategy.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 50